# Hexin Med

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hexin-med

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Total disclosed funding: $14M
- Latest round: Series A (Mar 2, 2023)
- Investors on record: 4

## About

Founded in 2020 and based in Suzhou, China, Hexin Med operates as a targeted drug provider, specializing in the development of targeted therapeutic integrated nucleotide drugs. The company's first product has received the Notice of Drug Clinical Trial from the State Drug Administration in June 2022. In May 2025, Hexin Med closed a venture funding from new investor China National Nuclear Corporation Capital. The company has developed core technologies for PET contrast agents and targeted radiotherapy. Hexin Med also provides medical solutions such as specific tumor diagnostic contrast agent development, integrated diagnostic and therapeutic drugs, and other targeted drugs. The main products include 68Ga-HX01, 68Ga, 177Lu dual-targeted therapeutic class 1 new drug and RDC drug. The company mainly generates revenue from the R&D of targeted therapeutic integrated nucleotide drugs.

## Funding rounds

- Series A, Mar 2, 2023, $14M — Cowin Capital, Sunland Capital, Yishang Huicheng Investment
- Angel, Feb 4, 2021 — GoldHold Wisdom Venture Capital

## Investors

- GoldHold Wisdom Venture Capital (https://capitalatlas.ai/funds/goldhold-wisdom-venture-capital) — Angel
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A
- Sunland Capital — Series A
- Yishang Huicheng Investment (https://capitalatlas.ai/funds/yishang-huicheng-investment) — Series A